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ABSTRACT 
Itraconazole is a first-generation triazole agent with an extended spectrum of activity; it is licensed in 
adults for superficial and systemic fungal infections; no recommendation has been yet established 
for use in children patients. Its variable and unpredictable oral bioavailability make it difficult to 
determine the optimal dosing regimen. Hence, therapeutic drug monitoring, highly available in 
clinical practice, may improve itraconazole treatment success and safety. The aim of the study was 
to describe in paediatrics the oral itraconazole pharmacokinetics, used for prophylaxis. Moreover, 
we evaluated the utility of its therapeutic drug monitoring in this cohort. A fully validated 
chromatographic method was used to quantify itraconazole concentration in plasma collected from 
paediatric patients, at the end of dosing interval. Associations between variables were tested using 
the Pearson test. Mann-Whitney U test has been used to probe the influence of categorical variables 
on continuous ones. Any predictive power of the considered variables was finally evaluated through 
univariate and multivariate linear and logistic regression analyses. A high inter-individual variability 
was shown; ethnicity (beta coefficient, β: -0.161 and interval of confidence at 95%, IC: -395.035;-
62.383) and gender (β: 0.123 and IC: 9.590; 349.395) remained in the final linear regression model 
with p value of 0.007 and 0.038, respectively. This study highlights that therapeutic drug monitoring 
is required to achieved an adequate target itraconazole serum exposure. 
 
KEYWORDS: therapeutic drug monitoring; itraconazole; HPLC; antifungal; invasive fungal infections; 
paediatrics. 
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1. INTRODUCTION  
Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality in children. 
Successful management of these systemic infections requires identification of the causative 
pathogen, appropriate antifungal selection, and optimisation of its pharmacokinetic and 
pharmacodynamic properties, to maximise its antifungal activity and minimise toxicity and the 
emergence of resistance (1). Azoles remain the first choice for prevention and treatment of IFIs(2); 
however, the clinical use of these drugs is characterized by frequent pharmacological disadvantage 
in terms of pharmacokinetic variability and drug-drug interactions (3).  
Itraconazole (ITC, Sporanox®) is a first-generation azole approved by the United States Food and 
Drug Administration (FDA) for the treatment of fungal infections; it is well tolerated and effective for 
superficial and systemic fungal infections; no recommendation has been yet established for use in 
children patients (4). ITC is lipophilic and it interferes with the synthesis of the cytochrome P450 
(CYP)-dependent enzyme lanosterold 14-α-emethylase, an ergosterol precursor essential for the 
fungal cell membranes (5, 6). ITC levels are 2 to 20 times higher in tissues, such as lungs, kidney, 
bone and muscles, skin, nails, and the female genital tract, than in the serum; nevertheless 
penetration into the cerebrospinal fluid is limited (7). It is metabolized in liver, yielding over 30 
different metabolites. In pediatric patients, ITC absorption rate from oral (OS) administration was 
found to be greater than capsules and higher drug plasma exposure has been observed in older 
children (5 to 12 years old) (8-12). 
Drug levels and treatment outcome depend on host factors, target organisms and associated 
interventions and therapeutic drug monitoring (TDM) can timely and appropriately guide drug 
dosage modifications (13). Already published clinical TDM studies have been conducted and they 
observed that ITC dose modification could result in more appropriate drug levels (14). The aim of our 
study was to describe, in paediatrics, the ITC OS pharmacokinetics, used for IFIs prophylaxis (OS 
administration), and to evaluate the utility of ITC TDM in this population. 
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2. RESULTS 
Mean, standard deviation (SD), median and median and interquartile range (IQR), 25th to 75th 
percentiles, values for age, body mass index (BMI) and ITC plasma concentrations were resumed and 
compared in table 1; there were no statistically significant differences in terms of baseline 
characteristics.  
The drug dosage has been evaluated with a score from 1 to 18, as showed in Table 2. 
Based on published ITC through levels cut-off for prophylaxis (9-11), we observed that 128 patients 
(44.1%; median 78.00 ng/mL, IQR: <limit of detection (LOD) - 148.00 ng/mL) showed sub-optimal 
exposure, whereas 162 subjects (55.9%; median 735.00 ng/mL; IQR: 431.50 - 1203.75 ng/mL) had 
concentrations higher than the efficacy defined level. 
A high interindividual variability was found between ITC Ctrough concentrations: the median value was 
306.50 ng/mL and the IQR range was 91.00 ng/mL and 781.25 ng/mL.  
Pearson test showed that there were no statistically significant correlation among ITC Ctrough and 
drug dose, BMI or age. Mann-Whitney U did not result in statistically significant influence of sex or 
ethnicity on ITC exposure. 
Univariate linear regression analysis was performed to evaluate the effect of ethnicity, gender, age, 
BMI and drug dose on ITC Ctrough. Stepwise forward regression analysis was used to identify the 
minimum set of independent predictive variables of ITC exposure and estimate the contribution of 
each factor to pharmacokinetic variability; only ethnicity (beta coefficient, β: -0.161 and interval of 
confidence at 95%, IC: -395.035;-62.383) and gender (β: 0.123 and IC: 9.590; 349.395) remained in 
the final model with p value of 0.007 and 0.038, respectively (Table 3).  
Univariate logistic regression analysis was carry out to evaluate the effect of age, gender, BMI and 
drug dose on ITC efficacy cut-off value of 250 ng/mL. Stepwise forward regression analysis was used 
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to identify the minimum set of independent predictive variables of the cut-off effectiveness and 
estimate the contribution of each factor to pharmacokinetic variability; no factors remained in the 
final model (table 4).  
 
3. DISCUSSION 
ITC pharmacokinetics are highly variable, probably due to its unpredictable oral bioavailability (15, 
16): it is non-linear (or saturable) exhibits prolonged clearance and  slow accumulation (17). The 
drug half-life is approximately 24 h and the time to steady state is about 14 days (16). ITC is a weakly 
basic Biopharmaceutics Classification System (BCS)(18) class II (low solubility/high permeability) drug 
with a pH-dependent dissolution (pKa value, 3.7); for this reason it requires an acidic gastric 
environment for adequate dissolution and absorption. In fact, ITC coadministration with gastric 
acidity inhibitors, such as antacids and proton pump inhibitors, reduce the extent of drug absorption 
(19, 20). ITC is a substrate of P-glycoprotein (P-gp), a membrane efflux transporter (21-24). 
 
Our results show that ITC exposure has a high interindividual variability and participants age, BMI, 
ethnicity, sex or age did not significantly influence ITC pharmacokinetics. Instead, linear regression 
analysis showed that ethnicity (p=0.007) and gender (p=0.038),  respectively are negative and 
positive, predictors of trough levels (Table 3). Gender-related differences, such as body size and 
muscle mass, may result in pharmacokinetic differences; genetic variations among ethnic groups 
also can alter drug disposition (25).  
 
Ethnicity may influence the disposition of P-gp-substrate drugs due to the of differences in P-gp 
polymorphism between black and white subjects. Especially, P-gp polymorphisms may influence ITC: 
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in a study on ITC, administered before fexofenadine, a P-gp substrate, the fexofenadine area under 
the concentration curve was significantly higher and the drug clearance significantly lower in 
individuals with TT phenotype than in GC haplotype, indicating P-gp inhibition by ITC in TT subjects 
(26). 
During the past decade many information about inter-gender differences has been published in 
adult population (25, 27-30). Considering the pharmacokinetic differences, an apparent high female 
CYP3A4 activity has been reported (31). Conversely, the activity of other CYP isozymes (e. g. 
CYP2C19, CYP2D6, and CYP2E1) and the glucuronidation activity may be higher in males (28, 29). 
Thus, different oral bioavailability, caused by different intestinal and hepatic metabolic enzymes 
activity, may be found. However, no evidence about children are still available. 
Moreover, women have lower acid secretion in the stomach (28), and then the ITC absorption might 
be compromised, due to its incomplete dissolution and unrestricted presystemic intestinal 
metabolism. Eventually, in a study on 639 cases of invasive candidiasis, non-white race and female 
gender were more commonly associated with non-albicans species (32). 
Evaluating the logistic regression analysis, performed to assess the effect of age, gender, BMI and 
drug dose on ITC efficacy cut-off for prophylactic use, no factors were retained in the final model 
(table 4). We chose to consider the steady-state itraconazole trough concentration of 250 ng/mL (9-
11) for our analyses, because it is the one used by our clinicians to discriminate prophylaxis 
outcome. Nevertheless, more recent publication describe a new threshold for prophylaxis of 500 
ng/mL (14, 33, 34).   
To our knowledge, in literature there are limited data describing the ITC use in children; ITC single 
intravenous or OS dose of 2.5 mg/kg/day in children aged 7 months to 17 years is well tolerated, but 
it results in a high variability in drug exposure (35). Moreover, OS dose of 5 mg/kg/day results in 
lower concentrations in infants compared with children older than 2 years of age (36).  
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ITC remains a key agent for the management of endemic mycoses worldwide and its broad spectrum 
of activity and availability (intravenous and OS route of administration) suggest that ITC  long-term 
use is affordable and practical. In addition, the ITC pharmacokinetic variability its numerous 
potential drug interactions prompt that TDM is clinically necessary in order to achieve safe and 
effective systemic drug exposures. The results from the present study might be further explained 
through pharmacogenetic analyses, which could explain posaconazole levels variability, also 
concerning gender, and why it is ineffective in some patients (37).  
Potential limitations to our study include its retrospective nature and a relatively small sample size; 
moreover it lacks of a standardized protocol for ITC dosing. Hence, further works applied to larger 
cohorts and which include the ITC active metabolite (hydroxyitraconazole) quantification are 
required to confirm the reported data.  
4. METHODS 
2.1 Patients and inclusion criteria 
Plasma samples were collected at the Laboratory of Clinical Pharmacology and Pharmacogenetics 
(Department of Medical Sciences, Unit of Infectious Diseases, University of Turin, Amedeo di Savoia 
Hospital, Turin) and Clinical Pharmacology Service "Franco Ghezzo" (Department of Biological and 
Clinical Sciences, University of Turin, S. Luigi Gonzaga Hospital) from different Hospitals in Piedmont 
(Italy). Inclusion criteria were: age below 18 years old, diagnosed IFI and treatment with oral ITC for 
prophylaxis, with an adherence of 90%. Patients on treatment with potential interacting drugs, 
allergy or intolerance to ITC, HIV infection, severe malnutrition, liver cirrhosis, chronic renal failure 
(with estimated creatinine clearance, eCRCl<60 mL/min) were excluded. Two hundred ninety 
paediatric patients (175 males, 60.3 %), treated with ITC, were enrolled. About half of them (51.7%; 
N=150) were Caucasians. All the enrolled patients received ITC antifungal prophylaxis and the route 
of administration was only OS.  
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The research related to human use has been complied with all the relevant national regulations, 
institutional policies and in accordance the tenets of the Helsinki Declaration, and has been 
approved by the authors' institutional local Ethics Committee (study protocol: "PkPG_J02AC Studio 
retrospettivo per la valutazione e farmacocinetica e farmaco-genetica della terapia antimicotica con 
farmaci triazolici”). A written informed consent for the study was obtained from each subject, signed 
by  natural/biological father or mother of a child with full parental legal rights. The primary aim of 
the approved protocol consist in: evaluation of triazoles plasma trough concentration at the steady 
state condition, and correlation of the obtained data with treatment outcome and toxicity.  
For all the patients, following data were available: gender, age, BMI, ethnicity and ITC dose. 
2.2 Determinations of ITC plasma concentration 
Patient blood samples (collected in lithium-heparin tube, 5 mL) were taken immediately before drug 
intake (Ctrough), under steady-state conditions (reached after two weeks of ITC oral solution). Plasma 
samples were obtained by centrifugation at 3000 rpm for 10 min at 4°C. 6,7-dimethyl-2,3-di(2-
pyridyl)quinoxaline (QX), used as the internal standard (IS), was purchased from Sigma-Alderich 
Corporation (Milan, Italy), and ITC was purchased from Sigma-Alderich Corporation (Milan, Italy). 
Acetonitrile (HPLC grade) and methanol (HPLC grade) were purchased from VWR (Milan, Italy). 
Formic acid was from Sigma-Alderich Corporation (Milan, Italy). HPLC-grade water was produced by 
a Milli-DI system coupled with a Synergy 185 system by Millipore (Milan, Italy). 
Two hundred μl of plasma samples were pipetted into a polytetrafluoroethylene tube, and 50 μl of IS 
working solution was added to each tube. Samples were extracted by protein precipitation using 200 
μl of acetonitrile. Each sample was vortexed for at least 15s and then centrifuged at 12,000 rpm for 
10 min at 4°C. One hundred μl of supernatant was transferred to a glass vial and diluted with 100 μl 
of water. Fifty μl of sample was then injected into the HPLC-MS system. All extraction procedures 
were performed at room temperature. The HPLC-MS system used was a Waters system (Milford, 
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MA), with a binary pump (model 1525), in-line degasser AF, 717-plus autosampler, and Micromass 
ZQ mass detector. The LC-MS Empower 2 Pro software program (version year 2005; Waters) was 
used (38, 39). 
Chromatographic separation was performed at 35°C, using a column oven, on a C18 Atlantis T-3 5-
μm (150 mm by 4.6 mm, inside diameter [i.d.]) column (Waters, Milford, MA), protected by a 
Security Guard with a C18 (4.0 mm by 3.0 mm, i.d.) precolumn (Phenomenex; CA). The mobile phase 
composed initially of 50:50 water with formic acid (0.05%)/acetonitrile with formic acid (0.05%) was 
then ramped to 20:80 within 6.5 min. The flow rate was set at 1 mL/min. 
Detector settings were as follows: electrospray ionization (ESI+); capillary voltage, 3.5 kV; source 
temperature, 110°C; desolvation temperature, 350°C; nitrogen desolvation flow, 400 L/h; nitrogen 
cone flow, 50 L/h. The ion m/z values monitored were: 353.2 for ITC and 313.4 for QX, cone voltage 
was 25 V and 50, respectively. 
The lower limit of quantification (LLOQ) was considered the lowest standard on the calibration 
curve. Therefore, the LLOQ for ITC was 0.031 µg/ml. The considered LOD was 0.015 µg/ml. Intra- and 
interday precision were calculated by determining the relative standard deviation (% RSD) at each 
QC concentration, as shown in Table 5. 
This work was carried out in a PHASE I AIFA, UNI EN ISO 9001:2008 and 13485:2012 (CE-IVD) 
certified laboratory. 
 
2.3 Statistical Analysis 
For descriptive statistics, continuous and non normal variables were summarized as average, SD, IQR 
25th to 75th percentiles was calculated to measure the statistical dispersion of the data; categorical 
variables were described as frequency and percentage. All the variables were tested for normality 
with the Shapiro-Wilk test. The correspondence of each parameter was evaluated with a normal or 
non-normal distribution, through the Kolmogorov-Smirnov test.  
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The Independent Samples t Test was used to compare the means of two independent groups, 
considering the level of statistical significance (p value<0.05). Pearson linear correlation coefficient 
(r) was used to investigate the strength of the association between two quantitative variables 
considering  the  level of statistical significance (p value<0.05). Mann-Whitney U test was used to 
probe the influence of categorical variables on continuous ones, considering the level of statistical 
significance (p value<0.05). Any predictive power of the considered variables was finally evaluated 
through univariate and multivariate linear (for pharmacokinetic parameters) and logistic 
(considering prophylaxis efficacy cut-off (9-11)) regression analyses. Factors with a p value <0.2 in 
univariate analysis were considered in multivariate analysis (p value <0.05). 
 
All the tests were performed with IBM SPSS Statistics 22.0 for Windows (Chicago, Illinois, USA). 
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Table 1. Mean, standard deviation, median and interquartile range for age, body mass index and 
itraconazole plasma concentrations. 
 
 
 
 
 
 
 
List of abbreviations: N, number; IQR, interquartile range; ITC, itraconazole; Ctrough, concentration 
at the end of dosing interval; BMI, body mass index. 
 
 
 
Variable 
N=290 
Mean 
Standard 
Deviation 
Median IQR 
Age (years) 8.56 4.36 9.00 5.00-12.00 
BMI Kg/m
2
 17.34 4.61 16.60 14.58-19.87 
ITC Ctrough ng/mL 579.14 713.23 306.50 91.00-781.25 
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Table 2. Number and percentage of patients for each dose regimens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of abbreviation: ITC, itraconazole; N, number; %, percentage; q.d., once daily; t.d., twice daily. 
 
  
N=290 
ITC dose 
Dose 
score N % 
1 20 t.d. 7 2.4 
2 25 t.d. 4 1.4 
3 30 t.d. 10 3.4 
4 40 t.d. 27 9.3 
5 45 t.d. 10 3.4 
6 50 t.d. 40 13.8 
7 60 t.d. 22 7.6 
8 70 t.d. 15 5.2 
9 75 t.d. 5 1.7 
10 80 t.d. 20 6.9 
11 100 q.d. 6 2.1 
12 100+50 4 1.4 
13 100 t.d. 67 23.1 
14 100+150 3 1.0 
15 100+200 151 5.2 
16 150 t.d. 4 1.4 
17 300 q.d. 5 1.7 
18 200 t.d. 26 9.0 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Table 3. Factors, in univariate and multivariate linear regression analysis, able to predict itraconazole 
plasma concentrations at the end of dosing interval.  
  Univariate Multivariate 
   p value β (IC 95%)  p value β (IC 95%) 
Ethnicity 0.021 -0.135 (-356.46; -28.99) 0.007 -0.161 (-395.04; -62.38) 
Age 0.727 -0.021 (-22.32; 15.59) 
  
Gender 0.124 0.090 (-36.47; 299.76) 0.038 0.123 (9.60; 349.40) 
BMI 0.987 -0.001 (-18.09; 17.81) 
  
ITC dose 0.681 -0.024 (-21.04; 13.77) 
  
 
β: β coefficient; IC95%: interval of confidence at 95%; in bold: values with a statistically significant p 
value; ITC, itraconazole; BMI, body mass index. 
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Table 4. Factors, in univariate and multivariate logistic regression analyses, able to predict itraconazole 
prophylaxis efficacy cut-off (250 ng/mL).  
  Univariate Multivariate 
   p value β (IC 95%)  p value β (IC 95%) 
Ethnicity 0.851 0.957 (0.60; 1.52) 
  
Age 0.378 1.024 (0.97; 1.08) 
  
Gender 0.061 1.581 (0.98; 2.56) 0.061 1.581 (0.98; 2.56) 
BMI 0.326 1.026 (0.98; 1.08) 
  
ITC dose 0.257 1.029 (0.98; 1.08) 
  
 
β: β coefficient; IC95%: interval of confidence at 95%; in bold: values with a statistically significant p 
value; ITC, itraconazole; BMI, body mass index. 
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Table 5. Itraconazole intra- and interday accuracy and precision.  
RSD: relative standard deviation.  
  Precision (% RSD) 
Nominal value (µg/mL) Accuracy (% deviation) Intraday Interday 
0.10 6.23 9.12 6.34 
1.50 2.30 4.30 8.70 
3.00 0.14 5.72 12.01 
5.00 4.60 7.86 12.64 
 
 
